News

Sildenafil May Treat PH by Limiting Cells That Induce Remodeling and Inflammation

Sildenafil appears to treat pulmonary hypertension (PH) by reducing the recruitment of bone marrow (BM)-derived progenitor cells, cells now being seen as potential key drivers of lung remodeling and inflammation in diseases that include PH. The study, “Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells,” was published in the…

BePHenomenal.com Aims to Educate and Engage People with PH

November is Pulmonary Hypertension Awareness Month and, in recognition, SteadyMed has announced the launch of its new website, BePHenomenal.com, dedicated to educating people with pulmonary hypertension (PH) so as to empower them to live the healthiest and most PHenomenal lives possible. The Pulmonary Hypertension Association notes…

Antipsychotic Agent with Potential as PAH Treatment Named Orphan Drug by FDA

The U.S. Food and Drug Administration (FDA) has designed Reviva Pharmaceuticals’ RP5063 an Orphan Drug as a potential treatment of pulmonary arterial hypertension (PAH), providing the company with developmental and testing assistance. “We are pleased to receive Orphan Drug Designation for RP5063, which emphasizes the significant need for new mediations for patients…

Exercise May Help IPAH Patients by Shifting Immune System Toward Healthier Balance

Physical exercise can modulate the immune response that activates inflammation in patients with idiopathic pulmonary arterial hypertension to improve their cardiopulmonary function and quality of life, a study published in the BMC Pulmonary Medicine reported. Pulmonary arterial hypertension (PAH) is a progressive vascular disease characterized by increased blood pressure in the lung vasculature,…

Early Data Support Oral Anti-Fibrotic Treatment, PBI-4050, for Pulmonary Hypertension

ProMetic Life Sciences recently presented positive preclinical data on its fibrosis-targeting lead candidate, PBI-4050, showing that the drug effectively reduces pulmonary hypertension and right ventricular hypertrophy. The company also presented positive effects of PBI-4050 on cardiovascular biomarkers in patients with metabolic syndrome and type 2 diabetes. The data…

Physical, Emotional and Financial Burden Felt by Caregivers of PAH Patients Spotlighted

The hardships felt by caregivers of patients with pulmonary arterial hypertension (PAH) are “multidimensional” — emotional, physical and economic — and those burdens should be recognized and caregivers’ own physical and psychological needs accounted for, as their work is increasingly necessary to societies in which patients are living longer, a recent review study argues. In the review, “…